---
schema_version: "secwatch.filing_event.v1"
accession: "0001689375-25-000002"
form_type: "8-K"
ticker: "TRDA"
cik: "0001689375"
company_name: "Entrada Therapeutics, Inc."
filed_at: "2025-02-03T23:59:59+00:00"
generated_at: "2026-05-27T04:00:28.923168+00:00"
event_type: "regulatory"
sentiment: "positive"
materiality_score: 0.6
calibrated_materiality_score: 0.6
confidence: "high"
source: SEC EDGAR
---

# Entrada gets UK MHRA nod for Phase 1/2 trial of DMD candidate ENTR-601-44

## Summary
- UK MHRA and REC authorized ELEVATE-44-201, a global Phase 1/2 MAD study of ENTR-601-44 for DMD exon 44 skipping.
- Dosing every 6 weeks across three cohorts (6-18 mg/kg); Part A safety/PK/PD, Part B efficacy.
- Company on track to initiate trial in Q2 2025; regulatory filings also submitted in US and EU.
- Prior Phase 1 single-dose study showed ENTR-601-44 well-tolerated with no serious adverse events.
- If eligible, participants may enter an open-label extension for longer-term safety/efficacy assessment.

## SEC filing metadata
- accession: 0001689375-25-000002
- form_type: 8-K
- ticker: TRDA
- cik: 0001689375
- company_name: Entrada Therapeutics, Inc.
- filed_at: 2025-02-03T23:59:59+00:00
- event_type: regulatory
- sentiment: positive
- materiality_score: 0.6
- calibrated_materiality_score: 0.6
- confidence: high
- sec_items: 7.01, 8.01, 9.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000002/0001689375-25-000002-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1689375/000168937525000002/trda-20250203.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001689375-25-000002
- JSON: https://secwatch.observer/filing/0001689375-25-000002.json
- Plain text: https://secwatch.observer/filing/0001689375-25-000002.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.